Royal Free Hospital

Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study (2018) Klompmaker S, Van Hilst J, Gerritsen SL, Adham M, Quer MTA, Bassi C, Berrevoet F, et al. Journal article Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study (2018) Klompmaker S, Van Hilst J, Gerritsen SL, Adham M, Albiol Quer MT, Bassi C, Berrevoet F, et al. Journal article, Erratum Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study (2018) Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, et al. Conference contribution Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article A randomised phase II study of Nivolumab plus Ipilimumab versus Standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2018) Ahrens M, Scheich S, Goekbuget N, Boleti E, Gruenwald V, Escudier B, Goebell P, et al. Conference contribution Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018) Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article